Business
LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy
LOS ANGELES, CA - February 12, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in ...
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"text","content":"LOS ANGELES, CA - February 12, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. "Rather than developing standalone treatments, LIXTE is advancing a first-in-class approach designed to increase the effectiveness of chemotherapy and immunotherapy across multiple cancer indications," reads a recent article. "At the center of LIXTE's strategy is protein phosphatase 2A, or PP2A, an enzyme that plays a critical role in regulating cell growth, DNA repair, and survival signaling. In many cancers, PP2A activity enables tumor cells to recover from the damage caused by treatment, contributing to resistance and disease progression LIXTE's proprietary compound, LB-100, is a small-molecule PP2A inhibitor designed to temporarily disrupt these repair mechanisms at the moment when cancer cells are exposed to therapy. Preclinical research cited in the company's presentation shows that this disruption can make tumor cells more vulnerable to chemotherapy and immunotherapy, increasing treatment effectiveness without introducing a new cytotoxic agent."","length":1279,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1293,"height":507,"url":"https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VCVJ6yC337nqarY7rX_X7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3NjtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":960,"height":376},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MmFuzfq1hlGGX6FrBtdqXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDI7Y2Y9d2VicA--/https://media.zenfs.com/en/newsmediawire_165/24e5e865c170c2b5e9a7a0400b575fd2","width":1200,"height":471}}},{"type":"text","content":"To view the full article, visit https://ibn.fm/IxVtt","length":52,"tagName":"p"},{"type":"text","content":"About LIXTE Biotechnology Holdings Inc.","length":39,"tagName":"p"},{"type":"text","content":"LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company focused on...